TY - JOUR
T1 - Structure-Based Optimization of Pyridoxal 5′-Phosphate-Dependent Transaminase Enzyme (BioA) Inhibitors that Target Biotin Biosynthesis in Mycobacterium tuberculosis
AU - Liu, Feng
AU - Dawadi, Surendra
AU - Maize, Kimberly M.
AU - Dai, Ran
AU - Park, Sae Woong
AU - Schnappinger, Dirk
AU - Finzel, Barry C.
AU - Aldrich, Courtney C.
N1 - Publisher Copyright:
© 2017 American Chemical Society.
PY - 2017/7/13
Y1 - 2017/7/13
N2 - The pyridoxal 5′-phosphate (PLP)-dependent transaminase BioA catalyzes the second step in the biosynthesis of biotin in Mycobacterium tuberculosis (Mtb) and is an essential enzyme for bacterial survival and persistence in vivo. A promising BioA inhibitor 6 containing an N-aryl, N′-benzoylpiperazine scaffold was previously identified by target-based whole-cell screening. Here, we explore the structure-activity relationships (SAR) through the design, synthesis, and biological evaluation of a systematic series of analogues of the original hit using a structure-based drug design strategy, which was enabled by cocrystallization of several analogues with BioA. To confirm target engagement and discern analogues with off-target activity, each compound was evaluated against wild-type (WT) Mtb in biotin-free and -containing medium as well as BioA under- and overexpressing Mtb strains. Conformationally constrained derivative 36 emerged as the most potent analogue with a KD of 76 nM against BioA and a minimum inhibitory concentration of 1.7 μM (0.6 μg/mL) against Mtb in biotin-free medium.
AB - The pyridoxal 5′-phosphate (PLP)-dependent transaminase BioA catalyzes the second step in the biosynthesis of biotin in Mycobacterium tuberculosis (Mtb) and is an essential enzyme for bacterial survival and persistence in vivo. A promising BioA inhibitor 6 containing an N-aryl, N′-benzoylpiperazine scaffold was previously identified by target-based whole-cell screening. Here, we explore the structure-activity relationships (SAR) through the design, synthesis, and biological evaluation of a systematic series of analogues of the original hit using a structure-based drug design strategy, which was enabled by cocrystallization of several analogues with BioA. To confirm target engagement and discern analogues with off-target activity, each compound was evaluated against wild-type (WT) Mtb in biotin-free and -containing medium as well as BioA under- and overexpressing Mtb strains. Conformationally constrained derivative 36 emerged as the most potent analogue with a KD of 76 nM against BioA and a minimum inhibitory concentration of 1.7 μM (0.6 μg/mL) against Mtb in biotin-free medium.
UR - http://www.scopus.com/inward/record.url?scp=85023759354&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85023759354&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.7b00189
DO - 10.1021/acs.jmedchem.7b00189
M3 - Article
C2 - 28594172
AN - SCOPUS:85023759354
SN - 0022-2623
VL - 60
SP - 5507
EP - 5520
JO - Journal of medicinal chemistry
JF - Journal of medicinal chemistry
IS - 13
ER -